Late-breaking positive Phase III data from ianalumab NEPTUNUS-1 and NEPTUNUS-2 trials in Sjögren’s disease to be presented Biomarker data informing use of investigational CAR-T cell therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback